Khan S, Araji G, Yetiskul E, Keesari PR, Haddadin F, Khamis Z, Chowdhry V, Niazi M, Afif S, Dhar M, El-Sayegh S. Systemic oncological therapy in breast cancer patients on dialysis. World J Clin Oncol 2024; 15(6): 730-744 [PMID: 38946836 DOI: 10.5306/wjco.v15.i6.730]
Corresponding Author of This Article
Salman Khan, MD, Academic Fellow, Academic Research, Department of Internal Medicine, Northwell Health - Staten Island University Hospital, 475 Seaview Ave, Staten Island, NY 10305, United States. skhan114@northwell.edu
Research Domain of This Article
Oncology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Jun 24, 2024; 15(6): 730-744 Published online Jun 24, 2024. doi: 10.5306/wjco.v15.i6.730
Systemic oncological therapy in breast cancer patients on dialysis
Salman Khan, Ghada Araji, Ekrem Yetiskul, Praneeth Reddy Keesari, Fadi Haddadin, Zaid Khamis, Varun Chowdhry, Muhammad Niazi, Sarah Afif, Meekoo Dhar, Suzanne El-Sayegh
Salman Khan, Ghada Araji, Ekrem Yetiskul, Praneeth Reddy Keesari, Fadi Haddadin, Zaid Khamis, Varun Chowdhry, Suzanne El-Sayegh, Department of Internal Medicine, Northwell Health - Staten Island University Hospital, Staten Island, NY 10305, United States
Muhammad Niazi, Meekoo Dhar, Department of Hematology and Oncology, Northwell Health - Staten Island University Hospital, Staten Island, NY 10305, United States
Sarah Afif, Department of Internal Medicine, CUNY School of Medicine, New York, NY 10031, United States
Author contributions: Khan S, Araji G, Yetiskul E, Keesari PR, Haddadin F, Khamis Z, Chowdhry V, Afif S, Dhar M, and El-Sayegh S designed the research study and performed the research, and contributed new reagents and analytic tools; Khan S, Araji G, Yetiskul E, Keesari PR, Haddadin F, Khamis Z, Chowdhry V, Niazi M, Afif S, Dhar M, and El-Sayegh S analyzed the data and wrote the manuscript; and all authors have read and approved the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Salman Khan, MD, Academic Fellow, Academic Research, Department of Internal Medicine, Northwell Health - Staten Island University Hospital, 475 Seaview Ave, Staten Island, NY 10305, United States. skhan114@northwell.edu
Received: March 24, 2024 Revised: May 12, 2024 Accepted: May 29, 2024 Published online: June 24, 2024 Processing time: 91 Days and 10.1 Hours
Abstract
The advancement of renal replacement therapy has significantly enhanced the survival rates of patients with end-stage renal disease (ESRD) over time. However, this prolonged survival has also been associated with a higher likelihood of cancer diagnoses among these patients including breast cancer. Breast cancer treatment typically involves surgery, radiation, and systemic therapies, with approaches tailored to cancer type, stage, and patient preferences. However, renal replacement therapy complicates systemic therapy due to altered drug clearance and the necessity for dialysis sessions. This review emphasizes the need for optimized dosing and administration strategies for systemic breast cancer treatments in dialysis patients, aiming to ensure both efficacy and safety. Additionally, challenges in breast cancer screening and diagnosis in this population, including soft-tissue calcifications, are highlighted.
Core Tip: Optimizing systemic breast cancer therapy in dialysis patients requires tailored approaches due to altered drug clearance and dialysis sessions’ necessity. This review emphasizes the significance of optimizing dosing and administration strategies, ensuring both efficacy and safety. Challenges in breast cancer screening, including soft-tissue calcifications, are highlighted, underlining the necessity for precise diagnostic strategies in this population. Furthermore, nuanced understanding and guidelines are imperative to navigate the complexity of oncological treatment in dialysis patients, ultimately enhancing patient outcomes.
